Clinical Trial: Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional
Official Title: A Multicenter, Open Label, Phase II Trial Evaluating Docetaxel + Anthracycline x 4 Cycles Followed by Docetaxel Single Agent x 4 Cycles as First-Line Therapy in Patients With Her2 Negative Locally Adv
Brief Summary:
Primary: To determine the pathological remission following the chemotherapy combination docetaxel and doxorubicin in large breast cancer
Secondary:
- Clinical response rate
- To investigate the safety of docetaxel doxorubicin combination in the treatment for neoadjuvant chemotherapy of breast cancer
- Type of surgery (radical/conservative)
Detailed Summary:
Sponsor: Sanofi
Current Primary Outcome: Primary 1. to determine the pathological remission following the chemotherapy combination docetaxel and doxorubicin in large breast cancer
Original Primary Outcome:
Current Secondary Outcome: Secondary: 1. Clinical response rate 2. to investigate the safety of docetaxel doxorubicin combination in the treatment for neoadjuvant chemotherapy of breast cancer 3. Type of surgery (radical/conservative)
Original Secondary Outcome:
Information By: Sanofi
Dates:
Date Received: April 17, 2007
Date Started: July 2004
Date Completion:
Last Updated: April 1, 2008
Last Verified: April 2008
